<DOC>
	<DOCNO>NCT00614614</DOCNO>
	<brief_summary>The purpose study characterize immunogenicity &amp; safety booster dose GSK Biologicals ' meningococcal vaccine 134612 give 12-15 month age 15-18 month age ( co-administered Infanrix速 ) healthy toddler prim GSK Biological 's Hib-meningococcal vaccine 792014 . This study single-blinded primary phase open-label booster phase .</brief_summary>
	<brief_title>Immuno , Safety GSK Vaccine 134612 Given Age 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014</brief_title>
	<detailed_description>The purpose study evaluate titer antibody serogroups A , C , Y W-135 safety booster dose GSK Biologicals ' meningococcal vaccine 134612 give toddler prim GSK Biological 's Hib-meningococcal vaccine 792014 . In addition , study provide immunogenicity safety data co-administration Infanrix meningococcal vaccine 134612 compare Infanrix administer alone . Depending group subject assign , one two blood sample take subject 's arm study . The protocol post update follow protocol amendment .</detailed_description>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parents/guardians comply requirement protocol . A male female , include , 6 12 week age ( + 6 day ) time first vaccination . Written inform consent obtain parent guardian subject . Healthy subject establish medical history clinical examination enter study . Born 36 week gestation . For inclusion booster phase , subject must receive three dos primary phase . Exclusion criterion enrolment ( primary phase ) Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug since birth . Planned administration/ administration vaccine foreseen study protocol within 30 day first dose study vaccine ( ) . Previous vaccination Neisseria meningitidis , Haemophilus influenzae type b , diphtheria , tetanus , pertussis , and/or poliovirus ; one previous dose hepatitis B vaccine . History Neisseria meningitidis , hepatitis B , Haemophilus influenzae type b , diphtheria , tetanus , polio pertussis disease . Any confirm suspected immunosuppressive immunodeficient condition base medical history physical examination History allergic disease reaction likely exacerbate component vaccine , dry natural latex rubber . Major congenital defect serious chronic illness . History neurologic disorder seizure . Acute disease time enrollment . Administration immunoglobulins and/or blood product since birth plan administration study period . Concurrent participation another clinical study , time study period , subject expose investigational noninvestigational product ( pharmaceutical product device ) . Exclusion criterion enrolment ( booster phase ) Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede entry booster phase ( Visit 4 ) , plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug since birth . Planned administration/administration vaccine foreseen study protocol within 30 day entry booster phase ( Visit 4 ) exception Prevnar速 Hib ( see follow three criterion ) ( Note ; license influenza vaccine allow throughout study ) Planned administration/administration fourth dose Prevnar速 within 30 day booster dose Infanrix速 Previous administration booster dose Hib prior entry booster phase . Previous administration primary dose Hib vaccine part study protocol . Previous vaccination Neisseria meningitidis part study protocol . Previous vaccination diphtheria , tetanus pertussis antigen outside primary phase study . History Neisseria meningitidis , Hib , diphtheria , tetanus pertussis disease . Any confirm suspected immunosuppressive immunodeficient condition base medical history physical examination . History allergic disease reaction likely exacerbate component vaccine , dry natural latex rubber . Major congenital defect serious chronic illness . History neurologic disorder seizure . Acute disease time enrollment . Administration immunoglobulins and/or blood product within past 3 month plan administration study period . Concurrent participation another clinical study , time study period , subject expose investigational noninvestigational product ( pharmaceutical product device ) .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Meningococcal disease</keyword>
	<keyword>Toddlers</keyword>
	<keyword>Neisseria meningitidis</keyword>
	<keyword>Meningococcal vaccine</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Human serum bactericidal assay</keyword>
	<keyword>Safety</keyword>
	<keyword>Vaccines , conjugate</keyword>
	<keyword>Booster vaccination</keyword>
</DOC>